Evidence map›Paper›PMID 41004067›Full record

ArticleClinical journal of gastroenterology2025

Remarkable response to durvalumab and tremelimumab in a patient with hepatocellular carcinoma: a case report.

Yosuke Osawa, Takayuki Akita, Yosuke Igarashi, Takaaki Ohtake

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yosuke OsawaDepartment of Gastroenterology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi, 329-2763, Japan. osawa-gif@umin.ac.jp.ORCID http://orcid.org/0000-0003-3581-1009
Takayuki AkitaDepartment of Gastroenterology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi, 329-2763, Japan.
Yosuke IgarashiDepartment of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi, 329-2763, Japan.
Takaaki OhtakeDepartment of Gastroenterology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi, 329-2763, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPredictive biomarkers for the efficacy of tremelimumab, a cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor, in hepatocellular carcinoma (HCC) have not yet been identified.

methodsWe report a case of HCC in which switching from bevacizumab plus atezolizumab to tremelimumab plus durvalumab after disease progression resulted in marked tumor regression, accompanied by the development of immune-related adverse event hepatitis. To explore the underlying mechanism, we performed immunohistochemical analysis of CD80, CD86, CD31, and CD3 expression in HCC tissue samples from 15 patients, including the present case.

resultsImmunohistochemistry for PD-L1 showed no detectable expression in the tumor tissue. CD80 (a co-stimulatory molecule that binds to CD28 and CTLA-4) was strongly expressed in hepatoma cells, with higher levels compared to the other cases. In contrast, CD86 (another co-stimulatory molecule) was observed in non-parenchymal cells, with relatively low expressions in this case. Similarly, the expression levels of CD31 (microvessel density marker) and CD3 (T lymphocyte marker) were also low.

conclusionStrong expressions of CD80 may have contributed to the therapeutic response by shifting its binding from CTLA-4 to CD28 following CTLA-4 blockade, thereby promoting T cell activation. CD80 expression may serve as a predictive biomarker for the efficacy of CTLA-4 blockade therapy.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsAgedAntibodies, Monoclonal, HumanizedB7-1 AntigenBevacizumabHumansMaleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-1 AntigenBevacizumabdurvalumabtremelimumabCD80Hepatocellular carcinomaTremelimumab

Identifiers

PMID41004067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.